Yehuda Handelsman Selected Research

Colesevelam Hydrochloride (Welchol)

7/2012	Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.
7/2012	Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.
1/2012	Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
7/2010	Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.
7/2010	Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.
5/2010	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.
1/2010	Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
11/2009	Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes.
5/2009	The role of colesevelam HCl in type 2 diabetes mellitus therapy.
5/2009	The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yehuda Handelsman Research Topics

Disease

45	Type 2 Diabetes Mellitus (MODY) 02/2020 - 05/2007
17	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 03/2007
11	Cardiovascular Diseases (Cardiovascular Disease) 10/2020 - 01/2017
7	Prediabetic State (Prediabetes) 01/2022 - 05/2009
5	Hypercholesterolemia 01/2020 - 02/2010
5	Weight Loss (Weight Reduction) 12/2018 - 09/2015
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2018 - 06/2016
4	Diabetes Mellitus 01/2020 - 01/2017
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2018 - 01/2017
4	Atherosclerosis 04/2018 - 01/2017
3	Hypertension (High Blood Pressure) 01/2022 - 05/2010
3	Heart Failure 01/2020 - 01/2017
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 04/2017
3	Weight Gain 01/2019 - 09/2015
3	Nausea 09/2018 - 10/2014
3	Stroke (Strokes) 09/2018 - 04/2017
3	Chronic Renal Insufficiency 04/2018 - 04/2017
3	Myocardial Infarction 04/2017 - 01/2017
2	Kidney Diseases (Kidney Disease) 10/2019 - 04/2018
2	Body Weight (Weight, Body) 09/2018 - 04/2014
2	Diarrhea 09/2018 - 10/2014
2	Hyperglycemia 09/2018 - 09/2015
2	Vomiting 09/2018 - 10/2014
2	Diabetes Complications 09/2018 - 09/2009
2	Vascular Diseases (Vascular Disease) 07/2017 - 05/2017
2	Acute Coronary Syndrome 04/2017 - 04/2017
2	Homozygous Familial Hypercholesterolemia 04/2017 - 04/2017
2	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 04/2017 - 04/2017
2	Thrombosis (Thrombus) 04/2017 - 01/2017
2	Infarction (Infarctions) 04/2017 - 01/2017
2	Insulin Resistance 04/2017 - 01/2013
2	Hyperlipidemias (Hyperlipidemia) 07/2012 - 11/2009
1	Atrial Fibrillation 01/2022
1	Cognitive Dysfunction 01/2022
1	Atrial Flutter (Flutter, Atrial) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2020
1	Fournier Gangrene 01/2019
1	Chronic Disease (Chronic Diseases) 11/2018
1	Anemia 04/2018
1	Endocrine System Diseases (Endocrine Diseases) 11/2017

Drug/Important Bio-Agent (IBA)

23	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 03/2007
16	Insulin (Novolin)FDA Link 02/2020 - 03/2007
13	LipidsIBA 01/2022 - 05/2009
12	LDL CholesterolIBA 01/2020 - 05/2009
10	Hemoglobins (Hemoglobin)IBA 01/2021 - 09/2009
10	Insulin Glargine (Lantus)FDA Link 02/2020 - 09/2009
10	oxidized low density lipoproteinIBA 01/2020 - 11/2009
10	Colesevelam Hydrochloride (Welchol)FDA Link 07/2012 - 05/2009
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 12/2012
7	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 01/2010
7	Triglycerides (Triacylglycerol)IBA 07/2017 - 07/2010
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 01/2012
6	insulin degludecIBA 02/2019 - 12/2012
6	Bile Acids and Salts (Bile Acids)IBA 05/2011 - 05/2009
5	Glucagon-Like Peptide-1 Receptor AgonistsIBA 02/2020 - 09/2018
5	CholesterolIBA 01/2020 - 04/2017
5	Pharmaceutical PreparationsIBA 09/2018 - 07/2012
5	Blood Glucose (Blood Sugar)IBA 03/2018 - 05/2010
4	lixisenatideIBA 02/2020 - 12/2018
4	Glucagon-Like Peptide-1 ReceptorIBA 02/2019 - 10/2014
4	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2018 - 12/2015
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 03/2018 - 04/2014
3	Sodium-Glucose Transport ProteinsIBA 01/2020 - 09/2015
3	SodiumIBA 01/2020 - 06/2016
3	dapagliflozinIBA 01/2020 - 01/2019
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2019 - 01/2010
3	omega-Chloroacetophenone (Mace)IBA 09/2018 - 04/2017
3	ApolipoproteinsIBA 04/2017 - 01/2017
3	Proprotein Convertase 9IBA 04/2017 - 01/2017
3	HDL CholesterolIBA 04/2017 - 01/2017
2	PCSK9 InhibitorsIBA 01/2020 - 01/2018
2	IDegLiraIBA 02/2019 - 02/2017
2	Liraglutide FDA Link 02/2019 - 02/2017
2	evolocumabIBA 01/2019 - 12/2017
2	semaglutideIBA 09/2018 - 09/2018
2	Adenosine Triphosphate (ATP)IBA 04/2017 - 04/2017
2	C-Reactive ProteinIBA 04/2017 - 04/2017
2	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2017 - 04/2017
2	VLDL CholesterolIBA 04/2017 - 04/2017
2	Fenofibrate (CiL)FDA LinkGeneric 04/2017 - 01/2017
2	BezafibrateIBA 04/2017 - 01/2017
2	Sodium-Glucose Transporter 2 InhibitorsIBA 06/2016 - 09/2015
2	Lipoproteins (Lipoprotein)IBA 01/2012 - 01/2010
2	Hormones (Hormone)IBA 09/2010 - 06/2008
1	Dronedarone FDA Link 01/2022
1	CanagliflozinIBA 10/2019
1	empagliflozinIBA 10/2019
1	saxagliptin FDA Link 01/2019
1	Exenatide (Byetta)FDA Link 09/2018
1	dulaglutideIBA 09/2018
1	Indicators and Reagents (Reagents)IBA 04/2018
1	Blood Proteins (Serum Proteins)IBA 04/2018
1	Glycated Serum ProteinsIBA 04/2018
1	Biosimilar PharmaceuticalsIBA 11/2017
1	2- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA 10/2017

Therapy/Procedure

22	Therapeutics 01/2022 - 03/2007
19	Glycemic Control 10/2019 - 05/2007
2	Injections 03/2018 - 08/2016
1	Secondary Prevention 01/2020